Emergency COVID-19 Variant Supplement for Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)
亚特兰大微系统工程护理点技术中心 (ACME POCT) 的紧急 COVID-19 变异补充品
基本信息
- 批准号:10476947
- 负责人:
- 金额:$ 1548.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-18 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAmbulancesBiomedical EngineeringBloodCardiacCardiologyCellular PhoneChild health careClinicalClinical ResearchClinical and Translational Science AwardsClinical assessmentsCollaborationsCountryCritical CareCritical IllnessDataDevelopmentDevice or Instrument DevelopmentDevicesDiagnosisDiagnosticDoctor of PhilosophyElectronicsEmergency SituationEngineeringEquilibriumFacultyFosteringFundingFutureGeneral PopulationGoalsGuidelinesHeadHealth Services ResearchHeartHeart DiseasesHeart failureHematologistHematologyHomeHospitalsInstitutesInternationalLeadershipLungLung diseasesMedical DeviceMedical TechnologyMedicineMicrofluidicsMonitorMovementNanotechnologyNational Heart, Lung, and Blood InstituteOrganPathologicPatientsPediatric HospitalsPhysiciansPhysicians&apos OfficesPlayPoint of Care TechnologyProcessPulmonologyRecording of previous eventsRoleSARS-CoV-2 variantSideSignal TransductionSleepSystemTechnologyTimeTraining ActivityTranslationsUnited States National Institutes of HealthUniversity HospitalsValidationbasecommercializationcostdiagnostic valuefeasibility testinghealth care deliveryinnovationmicrochipmicrosensormicrosystemsnoveloperationpoint of carepoint of care testingpoint-of-care diagnosticsportabilityprogramsprototyperesearch clinical testingsensorsoundsuccesstechnology developmenttechnology traininguptakeusability
项目摘要
The advent of point-of-care (POC) diagnostic capabilities has enabled rapid and timely clinical evaluation in the
physician's office, an ambulance, the home, the field, or in the hospital and has the potential to significantly
impact health care delivery. In cardiology, pulmonology/critical care, and hematology, POC testing plays an
especially significant role as the heart and lungs are among the most vital of organs necessitating real time
diagnosis and rapid management during critical illnesses, while pathologic alternations in blood are associated
with critical, systemic illness. One class of novel medical technologies that is showing promise for POC
applications are microsystems-engineered technologies, that is, microchip-enabled devices ranging from
microelectromechanical systems (MEMs)-based sensors, microfluidics, to even smartphone-based systems.
Notable for their small size and power requirements, microchip-based systems provide the portability that is
vital for POC testing. In addition, the capability of microsystems to convert sound and movement into electrical
signals enable these technologies to be ideal devices to sense the dynamics of the lungs and heart and
therefore to diagnose and monitor pulmonary and cardiac disorders. Moreover, microsystems engineering has
brought forth the field of microfluidics, which is steadily finding applications for blood-based diagnostics, and
therefore, hematologic applications. To that end, per the NHLBI's U54 POCTRN guidelines, the overall goal of
the Atlanta Center for Microsystems Engineered POC Technologies (ACME POCT) is to assist and enable
inventors from across the country who have developed microsystems-based POC technologies for cardiac,
pulmonary, hematologic and sleep applications that are beyond proof-of-concept to define their specific clinical
needs, conduct clinical validation, and refine their technology, with the objective of accelerating the path to
translation and clinical adoption and directly addressing the barriers thereof. The ACME POCT uniquely
leverages Atlanta's nationally top-ranked clinical programs at Emory University's hospitals and Children's
Healthcare of Atlanta, one of the nation's largest pediatric hospital systems, as well the internationally
acclaimed microsystems engineering expertise at Georgia Tech, which includes the Institute for Electronics
and Nanotechnology (IEN), and other one-of-a-kind medical device prototyping, innovation, and testbed
facilities. The ACME POCT PI's uniquely balance the engineering and clinical sides of the Center and
comprise Wilbur Lam, MD, PhD, a clinical hematologist at Emory and Georgia Tech bioengineer with expertise
in POC diagnostic development and commercialization, Oliver Brand, PhD, a renowned microsystems
engineer and head of Georgia Tech's IEN, and Greg Martin, MD, MSc, a clinical pulmonologist at Emory and
head of clinical research in Atlanta's NIH-funded CTSA. Importantly, the leadership of the ACME POCT has a
history of collaboration and track record in managing Centers that have fostered medical device development.
护理点(POC)诊断功能的出现使快速和及时的临床评估成为可能
医生的办公室、救护车、家庭、现场或医院,并且有可能显著
影响医疗服务的提供。在心脏病学、肺病学/重症监护和血液学中,POC检测发挥着重要作用
心脏和肺是最重要的器官之一,需要实时
在危重疾病期间的诊断和快速处理,同时血液中的病理变化与
患有严重的系统性疾病。一类显示出PoC前景的新型医疗技术
应用是微系统工程技术,即支持微芯片的设备,范围从
基于微电子机械系统(MEMS)的传感器、微流体,甚至基于智能手机的系统。
基于微芯片的系统以其体积小和功耗要求而闻名,它提供了
对于PoC测试至关重要。此外,微系统将声音和运动转换为电能的能力
信号使这些技术成为感知肺和心脏动态的理想设备,并
因此,诊断和监测肺和心脏疾病。此外,微系统工程已经
带来了微流体领域,这一领域正在稳步找到基于血液的诊断的应用,以及
因此,血液学的应用。为此,根据NHLBI的U54 POCTRN指南,
亚特兰大微系统工程POC技术中心(ACME POCT)将协助和启用
来自全国各地的发明家,他们开发了基于微系统的心脏POC技术,
肺、血液学和睡眠应用超出概念验证以定义其特定的临床应用
需求,进行临床验证,并改进他们的技术,目标是加速实现
翻译和临床采用,并直接解决其障碍。ACME的观点是唯一的
利用亚特兰大埃默里大学医院和儿童医院的全国一流临床项目
亚特兰大的医疗保健,美国最大的儿科医院系统之一,以及国际
佐治亚理工学院广受赞誉的微系统工程专业知识,其中包括电子研究所
和纳米技术(Ien),以及其他独一无二的医疗设备原型、创新和试验台
设施。ACME POCT PI独一无二地平衡了中心的工程和临床方面,并
包括Wilbur Lam,医学博士,Emory的临床血液学家和佐治亚理工学院的具有专业知识的生物工程师
在PoC诊断开发和商业化方面,著名的微系统公司Oliver Brand,PhD
乔治亚理工学院的工程师兼负责人格雷格·马丁,医学博士,硕士,埃默里大学和
亚特兰大国立卫生研究院资助的CTSA的临床研究负责人。重要的是,ACME POCT的领导层有一个
在管理促进医疗器械开发的中心方面的合作历史和跟踪记录。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wilbur A Lam其他文献
Effect of Epitope Specific Antibodies on Single Platelet Physiology with Implications for Immune Thrombocytopenia Purpura
- DOI:
10.1182/blood-2022-159547 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Nina Shaver;Oluwamayokun Oshinowo;Meredith E. Fay;David R. Myers;Wilbur A Lam - 通讯作者:
Wilbur A Lam
Wilbur A Lam的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wilbur A Lam', 18)}}的其他基金
Engineering biophysical microtechnologies for hematologic applications in health and disease
工程生物物理微技术在健康和疾病中的血液学应用
- 批准号:
10579951 - 财政年份:2019
- 资助金额:
$ 1548.19万 - 项目类别:
Engineering biophysical microtechnologies for hematologic applications in health and disease
工程生物物理微技术在健康和疾病中的血液学应用
- 批准号:
10350610 - 财政年份:2019
- 资助金额:
$ 1548.19万 - 项目类别:
Engineering biophysical microtechnologies for hematologic applications in health and disease
工程生物物理微技术在健康和疾病中的血液学应用
- 批准号:
9898450 - 财政年份:2019
- 资助金额:
$ 1548.19万 - 项目类别:
SBIR phase II: A personalized, non-invasive hemoglobin level monitoring and management platform for chronic anemia patients.
SBIR II 期:针对慢性贫血患者的个性化、无创血红蛋白水平监测和管理平台。
- 批准号:
10458078 - 财政年份:2018
- 资助金额:
$ 1548.19万 - 项目类别:
SBIR phase II: A personalized, non-invasive hemoglobin level monitoring and management platform for chronic anemia patients.
SBIR II 期:针对慢性贫血患者的个性化、无创血红蛋白水平监测和管理平台。
- 批准号:
10325763 - 财政年份:2018
- 资助金额:
$ 1548.19万 - 项目类别:
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)
亚特兰大微系统工程护理点技术中心 (ACME POCT)
- 批准号:
10715493 - 财政年份:2018
- 资助金额:
$ 1548.19万 - 项目类别:
Redefining Clinical Viscosity in Sickle Cell Diseaseby Leveraging Microfluidic Technologies
利用微流体技术重新定义镰状细胞病的临床粘度
- 批准号:
10022309 - 财政年份:2018
- 资助金额:
$ 1548.19万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 1548.19万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 1548.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 1548.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 1548.19万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 1548.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 1548.19万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 1548.19万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 1548.19万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 1548.19万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 1548.19万 - 项目类别:
Standard Grant














{{item.name}}会员




